What happens when you take phenytoin with vitamin D?
Phenytoin is a potent inducer of hepatic cytochrome P450 enzymes. Two of those enzymes — CYP3A4 and CYP24A1 — happen to be the same enzymes that catabolize 25-hydroxyvitamin D (the main storage form of vitamin D) and its active hormone 1,25-dihydroxyvitamin D into inactive, water-soluble metabolites that are then excreted. With CYP induction, vitamin D is essentially being burned off faster than it can be replenished from sun exposure or normal dietary intake.
The mechanism was clarified in a landmark 2013 study in the Journal of Bone and Mineral Research that showed how the steroid and xenobiotic receptor (SXR/PXR), activated by phenytoin and similar drugs, induces CYP3A4 in the liver and intestine and accelerates 4-hydroxylation of 25(OH)D. Healthy volunteers given enzyme-inducing drugs for as little as two weeks saw their serum 25(OH)D drop by up to 70 percent.
Over months of phenytoin therapy, the cascade looks like this: serum 25(OH)D falls, less calcium is absorbed from the gut, ionized calcium dips, parathyroid hormone (PTH) rises in a compensatory effort, and the elevated PTH pulls calcium out of bone. The clinical name for the eventual outcome is anticonvulsant-induced osteomalacia (in adults) or rickets (in children), and the more silent end of the spectrum is osteopenia, osteoporosis, and an increased fracture risk that epidemiological studies put at roughly 1.2 to 2.4 times baseline.
Why is this important?
Bone disease from anticonvulsants is often clinically silent for years. By the time a patient presents with bone pain, proximal muscle weakness, or — worst case — a fragility fracture, significant bone has already been lost. Pediatric patients are particularly vulnerable: their skeletons are still being built, and impaired bone mineralization during growth can leave lasting deficits. Adults with limited sun exposure, dark skin, obesity, malabsorption (e.g., post-bariatric surgery, celiac disease), or who are housebound or institutionalized are also at higher risk.
A 2006 review and multiple subsequent studies have confirmed that long-term phenytoin users have meaningfully lower 25(OH)D, higher PTH, higher markers of bone turnover, and lower bone mineral density than matched controls. The UK Medicines and Healthcare products Regulatory Agency (MHRA) and other regulators have issued specific safety communications urging clinicians to monitor bone health in patients on long-term enzyme-inducing antiepileptic drugs.
What should you do?
If you are on phenytoin for more than a few months, ask your prescriber to order a baseline 25-hydroxyvitamin D level, serum calcium, phosphate, alkaline phosphatase, and PTH. Many neurology guidelines recommend repeating 25(OH)D at least annually.
Most patients on long-term enzyme-inducing anticonvulsants will need supplemental vitamin D3 (cholecalciferol), typically 1,000 to 2,000 IU per day, although individuals who are already deficient often need a higher loading regimen (for example, 50,000 IU weekly for 8 to 12 weeks) followed by maintenance dosing. Calcium intake (food plus supplements if needed) of around 1,000 to 1,200 mg per day is usually targeted, and weight-bearing exercise plus reasonable sun exposure help.
After several years on phenytoin, ask about a DXA (bone-density) scan, especially if you have other risk factors such as low body weight, smoking, glucocorticoid use, or a family history of osteoporosis. Track your supplements, sun exposure habits, and any unexplained bone pain or weakness in Pilora so the data is at hand for follow-up labs.
Which specific products are affected?
The interaction applies to all phenytoin and fosphenytoin products (Dilantin, Phenytek, Cerebyx, generics). The same mechanism — and a similar magnitude of effect — applies to other strong enzyme-inducing anticonvulsants including phenobarbital, primidone, carbamazepine, oxcarbazepine, and to a lesser degree topiramate. Newer non-inducing anticonvulsants such as levetiracetam, lamotrigine, and lacosamide appear to have less effect on vitamin D, though data are still accumulating.
On the supplement side, vitamin D3 (cholecalciferol) is generally preferred over vitamin D2 (ergocalciferol) for routine replacement because it raises 25(OH)D more efficiently. Activated forms such as calcitriol or alfacalcidol are sometimes used in refractory anticonvulsant-induced osteomalacia, but they should only be prescribed under specialist guidance because they bypass renal regulation and can cause hypercalcemia.
The bottom line
Phenytoin steadily depletes vitamin D by inducing the liver enzymes that catabolize it, and the downstream consequence is impaired calcium absorption, secondary hyperparathyroidism, and a real increase in osteomalacia and fracture risk. If you are on long-term phenytoin, baseline and annual 25(OH)D monitoring with vitamin D3 supplementation in the 1,000 to 2,000 IU per day range is now considered standard practice, not optional.